About: Terry Nolan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Terry Nolan Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Australian paediatrician and clinical epidemiologist

Attributes	Values
rdf:type	Item
description	investigador (es) wetenschapper (nl) дослідник (uk) Australian paediatrician and clinical epidemiologist (en)
rdfs:label	Terry Nolan (en) Terry Nolan (nl) Terry Nolan (sq)
skos:prefLabel	Terry Nolan (en) Terry Nolan (nl) Terry Nolan (sq)
name	Terry Nolan (en) Terry Nolan (nl) Terry Nolan (sq)
given name	wds:Q87056238-213FE71F-6FCA-46EE-8EB5-1E9C2136319F
given name	Terry
instance of	wds:Q87056238-4E965D6B-370A-4989-A745-CDD186028739
instance of	Homo sapiens
award received	wds:Q87056238-78285df5-45dc-ff2c-6835-4fbebb2047d3
award received	Officer of the Order of Australia
skos:altLabel	Terence Michael Nolan (en)
occupation	wds:Q87056238-95b4e039-4a37-b0a6-651a-164c67a69379 wds:Q87056238-e995c2a1-4d98-f89e-bd44-cae86cb427e0
employer	wds:Q87056238-1865A52D-C109-44CB-BD53-5D0F819ADDA9 wds:Q87056238-8D2527B3-E06B-4A0C-A6D5-6CC6211A9A25
NLA Trove people ID	wds:Q87056238-505AA443-A3C0-47D0-94D9-CB7386181DDE
sex or gender	wds:Q87056238-7496e416-4889-8334-3e3e-18dd14cca4ab
educated at	wds:Q87056238-04f3d45f-4706-a66a-bacd-f9d5c9f93422 wds:Q87056238-bde2a57e-49e1-587a-43c6-5fd68d992a4f
occupation	epidemiologist pediatrician
employer	University of Melbourne
NLA Trove people ID	596946
sex or gender	male
educated at	McGill University University of Western Australia
ORCID iD	wds:Q87056238-A9DA27E0-A22A-49F8-BD41-5A7149DA355B
ORCID iD	https://orcid.org/0000-0001-6018-3863
ORCID iD	0000-0001-6018-3863
The Conversation author ID	wds:Q87056238-7D75D254-EEFD-4F6B-8325-8FB157FDA7F3
The Conversation author ID	4044
ResearcherID	wds:Q87056238-424F29B7-D3AB-469B-AF6C-86BE5A886260
ResearcherID	A-2236-2008
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q87056238
is author of	A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children Seroprevalence of antibody to influenza A(H1N1)pdm09 attributed to vaccination or infection, before and after the second (2010) pandemic wave in Australia. Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study Improving influenza vaccination coverage in pregnancy in Melbourne 2010-2011. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children Seroprevalence of 2009 pandemic influenza A(H1N1) virus in Australian blood donors, October - December 2009. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. Panvax(®): a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. Optimal dosing and dynamic distribution of vaccines in an influenza pandemic. Detection of a divergent Parainfluenza 4 virus in an adult patient with influenza like illness using next-generation sequencing Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY) A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine A positive approach to parents with concerns about vaccination for the family physician Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants DTPa-HBV-IPV vaccine for primary vaccination of infants Household transmission of respiratory viruses - assessment of viral, individual and household characteristics in a population study of healthy Australian adults. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Five-year Antibody Persistence and Safety After a Single Dose of Combined Haemophilus influenzae Type B Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine in Haemophilus influenzae Type B-primed Toddlers Prevalence and Incidence of Respiratory Syncytial Virus and Other Respiratory Viral Infections in Children Aged 6 Months to 10 Years With Influenza-like Illness Enrolled in a Randomized Trial Respiratory viruses and influenza-like illness: Epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1-11 years. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities Increases in vaccination coverage for children in child care, 1997 to 2000: an evaluation of the impact of government incentives and initiatives. The cost of seasonal respiratory illnesses in Australian children: the dominance of patient and family costs and implications for vaccine use. Deep sequence characterisation of a divergent HPIV-4a from an adult with prolonged influenza-like illness Safety and tolerability of a cell culture derived trivalent subunit inactivated influenza vaccine administered to healthy children and adolescents: A Phase III, randomized, multicenter, observer-blind study Making sense of perceptions of risk of diseases and vaccinations: a qualitative study combining models of health beliefs, decision-making and risk perception IMMEDIATE AND LONGER TERM IMMUNOGENICITY OF A SINGLE DOSE OF THE COMBINED HAEMOPHILUS INFLUENZAE TYPE B-NEISSERIA MENINGITIDIS SEROGROUP C-TETANUS TOXOID CONJUGATE VACCINE IN PRIMED TODDLERS 12 TO 18 MONTHS OF AGE Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age Influence of contact definitions in assessment of the relative importance of social settings in disease transmission risk The WHO position on rabies immunization - 2018 updates Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysi Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine FluMum: a prospective cohort study of mother-infant pairs assessing the effectiveness of maternal influenza vaccination in prevention of influenza in early infancy. Booster vaccination of toddlers with reduced antigen content diphtheria -- tetanus -- acellular pertussis vaccine Antibody persistence in Australian adolescents following meningococcal C conjugate vaccination Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine The Safety of Influenza and Pertussis Vaccination in Pregnancy in a Cohort of Australian Mother-Infant Pairs, 2012-2015: The FluMum Study Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Persistence of Bactericidal Activity at 4 Years After 2 Primary Doses of a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 188 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software